You are here: Industry Insights > NVX-CoV2373

News List

Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact contractpharma
September 27, 2020
Par Sterile's Rochester facility began production of NVX-CoV2373 final drug product, with initial batches to be used in Novavax' Phase III trial.
Canadian government strikes deals with Janssen and Novavax for COVID-19 vaccines europeanpharmaceuticalreview
September 03, 2020
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
Novavax and Canada reach agreement in principle for 76 mn doses of COVID-19 vaccine expresspharma
September 02, 2020
Novavax has announced that it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine.
Novavax to Supply 76M Doses of COVID-19 Vax to Canada contractpharma
September 01, 2020
Pending finalized advance purchase agreement, Novavax will supply doses of NVX-CoV2373 beginning as early as 2Q21.
First patients enrolled in Phase II trial of Novavax COVID-19 vaccine europeanpharmaceuticalreview
August 26, 2020
The Phase II clinical trial to study NVX-CoV2373, the Novavax COVID-19 vaccine candidate, has enrolled its first patient.
Novavax commences Phase 2 clinical trial of COVID-19 vaccine candidate expresspharma
August 25, 2020
Trial to enroll up to 1,500 volunteers in the US and Australia, with approximately 50 per cent between 60 and 84 years of age.
UK Govt. Buys 60 Million Doses of Novavax’ COVID-19 Vax Candidate contractpharma
August 18, 2020
Fujifilm Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UK.
Novavax announces collaboration with SK bioscience for COVID-19 vaccine expresspharma
August 14, 2020
SK bioscience will manufacture the vaccine antigen component for use in the final drug product globally during the pandemic period.
AGC Biologics, Novavax Expand Coronavirus Vax Pact contractpharma
August 12, 2020
Expands supply of Matrix-M adjuvant for Novavax’ coronavirus vaccine, NVX-CoV2373, from its facility in Seattle for U.S. supply.
Novavax’s COVID-19 vaccine produces immune response in early study pharmatimes
August 07, 2020
Novavax has reported positive results from the Phase I portion of its Phase I/II study of its COVID-19 vaccine candidate NVX-CoV2373.

Previous page 1 2 3 4 5 6 7 Next page